ClinicalTrials.gg
RecruitingNCT03821857SEED-ADUpdated Nov 24, 2025

Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease

A Phase 4 interventional study of 18-F-Flortaucipir in Alzheimer Disease, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to female participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-24.

Sponsored by Mayo Clinic · Phase 4, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jun 2019; still recruiting 7 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
614
Allocation
Not applicable
Ages
60 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.

Planned enrollment
Largest of 22
614 · median 70
Started
2019
with 2 others
Phase 4
Only one
of the 22
Registered
17th of 22
by date
Lead sponsor
2 of 22
Mayo Clinic

Among the 22 studies testing flortaucipir in Alzheimer Disease, this one has the largest planned enrollment, is one of 3 that started in 2019, is the only one in phase 4, and was the 17th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About flortaucipir

flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing flortaucipir in Alzheimer Disease, or all of them as a file.
02

Study summary

The researchers are trying to determine whether ovarian hormones are associated with aging processes and with the risk of developing Alzheimer's disease in women.

Read the detailed description

The proposed project will enroll a total of 614 women.

Mayo Clinic Rochester Participants: Each women will have 2-3 clinic visits consisting of cognitive testing, tests of physical function, questionnaires, and a blood draw. All women will also undergo clinical neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451. All participants will have previously participated and will return by invitation only.

Mayo Clinic Jacksonville Participant: Only African American Women will be enrolled at this site. Each women will have 1-3 clinic visits consisting of physical function testing and neuroimaging, which includes structural MRI, β-amyloid (Aβ) deposition on PET as a biomarker of Aβ pathology, and tau deposition on PET as a marker of neurofibrillary tangles using AV-1451.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Mayo Clinic Rochester-

Inclusion Criteria:

  • Women who previously participated in this study
  • Currently aged 60 years and older
  • More than six months post chemotherapy or major surgery requiring general anesthesia
  • Willing and able to sign

Exclusion Criteria:

  • Not able to read and speak English
  • In hospice
  • Claustrophobic
  • If undergoing Tau imaging, cannot have

Mayo Clinic Jacksonville-

Inclusion Criteria:

  • African American Women
  • Currently aged 60 years and older
  • More than six months post chemotherapy or major surgery requiring general anesthesia
  • Willing and able to sign informed consent

Exclusion Criteria:

  • Not able to read and speak English
  • In hospice
  • Claustrophobic
  • If undergoing Tau imaging, cannot have QT Prolongation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
614 participants (estimated)

Study arms

  • Experimental
    Women

    18F-Flortaucipir and 11C-Pittsburgh compound-B radioligands will be used for experimental PET imaging of beta-amyloid and neurofibrillary tau pathology

    Drug: 18-F-Flortaucipir

Interventions

  • DrugFlortaucipirStudies of FlortaucipirFlortaucipir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Radioligands for PET imaging of beta-amyloid and neurofibrillary tangle tau pathology

    Also known as: 11C-Pittsburgh Compound-B

06

What researchers measure

Primary outcomes

  1. 18F-Flortaucipir PET imaging

    Cortical 18F-Flortaucipir PET imaging measured once in each participant

    Time frame: 1 day

  2. Pittsburgh compound-B PET imaging

    Global cortical SUVR measured once in each participant

    Time frame: 1 day

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Kantarci K, Kapoor E, Geske JR, Castillo A, Fields JA, Kara F, Knyazhanskaya EE, Schwarz CG, Senjem ML, Bailey KR, Lowe V, LeBrasseur NK, Rocca WA, Mielke MM. Premenopausal bilateral oophorectomy and Alzheimer's disease imaging biomarkers later in life. Alzheimers Dement. 2025 Jul;21(7):e14469. doi: 10.1002/alz.14469. Epub 2024 Dec 23. PubMed 39711285 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2019 (actual). Primary completion is estimated for May 2030, 131 months after the start.

Of 42 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 131 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2019
First posted
Jan 30, 2019
StartActual
Jun 27, 2019
Primary completionEst.
May 2030
CompletionEst.
May 2030
Last update
Nov 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03821857
Lead sponsor
Mayo Clinic
Responsible party
Kejal Kantarci (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Jan 30, 2019
Start date
Jun 27, 2019
Primary completion
May 2030 (estimated)
Completion
May 2030 (estimated)
Last update
Nov 24, 2025

Study contacts

June Kendall-Thomas, CRC
Contact
kendallthomas.june15@mayo.edu
507-293-9397
Desirae Howe-Clayton, CRC
Contact
howe.desirae@mayo.edu
507-255-0111
Kejal Kantarci, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion